Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07136623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

Study acronym: EKO-PH
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 1 of 2 sitesv5
  2. Notable Primary and study completion pushed from Aug 1, 2026 to May 31, 2027v4
  3. Minor Study sites: 1 to 2v3
  4. Notable Primary endpoint revised
    • Interventions: Digital stethoscope phonocardiogram + three-lead electrocardiogram (Eko CORE 500) (Diagnostic Test) to Eko CORE 500 phonocardiogram (PCG) recording (Diagnostic Test), Eko CORE 500 three-lead electrocardiogram (ECG) recording (Diagnostic Test)
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 67 words
    v2
  5. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1,925 trials monitored
See 99 trials at risk
This prospective, observational study will evaluate whether synchronized heart sound (phonocardiogram, PCG) and three-lead electrocardiogram (ECG) recordings (entered as separate interventions in PRS, though collected together in practice) collected with the Eko CORE 500 can help screen for pulmonary hypertension (PH). Adults (≥18 years) undergoing clinically indicated transthoracic echocardiography (TTE) and/or right heart catheterization (RHC) will complete one study visit (\~20 minutes). During the visit, study staff will obtain at least four 15-second CORE 500 recordings (aortic, pulmonic, tricuspid, and mitral areas). The clinical echocardiogram (and RHC, if performed) within ±7 days of the recordings will provide reference labels for the presence and severity of PH; de-identified demographic and clinical data may also be abstracted from the medical record. The primary objective is to develop and validate a software algorithm to detect PH and, where possible, stratify severity using noninvasive PCG+ECG signals. These recordings are investigational data acquisitions for algorithm development only; they are not diagnostic procedures and will not be used for clinical decision-making. Primary performance measures are sensitivity and specificity versus echocardiogram and RHC references. No clinical decisions will be based on the investigational algorithm, and no changes to standard care are required. The study plans to enroll up to \~1,513 participants to obtain approximately 1,375 evaluable datasets across multiple outpatient sites.
Trial Details
NCT Number NCT07136623
Lead Sponsor Eko Devices, Inc.
Conditions
(from sponsor)
Pulmnary Hypertension
Related terms Hypertension, Pulmonary
Enrollment 1,513 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov